Key result
Aspirin for thromboprophylaxis after primary lower limb arthroplasty was associated with low rates of PE (0.6-1.47%) and a significant decline in the 90-day standardized mortality ratio (P=0.024).
Why the study?
Does aspirin as primary thromboprophylaxis prevent DVT, PE, and death in patients undergoing primary lower limb arthroplasty?
Population
11,459 patients who underwent total hip, total knee or unicompartmental knee arthroplasty between November…
Comparison
Aspirin as the primary agent for pharmacological… vs Corresponding data in the National Joint…
Design
Cohort
Follow-up
90 days
Authors
Loading...
May support aspirin in multimodal arthroplasty prophylaxis; extends observational data but leaves randomized confirmation open.
Cohort (n=11,459)
Does aspirin as primary thromboprophylaxis prevent DVT, PE, and death in patients undergoing primary lower limb arthroplasty?
Effect estimate: SMR decline from 86.5 to 39.7
p-value: p=0.024
Aspirin is safe and effective as the primary thromboprophylactic agent following primary lower limb arthroplasty when used as part of a multimodal approach.
Ogonda et al. (2016) conducted a cohort in Primary lower limb arthroplasty (n=11,459). Aspirin vs. National Joint Registry for England and Wales (NJR) data was evaluated on Incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and 90-day all-cause mortality (SMR decline from 86.5 to 39.7, p=0.024). Aspirin for thromboprophylaxis after primary lower limb arthroplasty was associated with low rates of PE (0.6-1.47%) and a significant decline in the 90-day standardized mortality ratio (P=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: